Fig. 1

NAPSI, PASI, and DLQI through week 48 by treatment subgroup (a–e). a) Guselkumab, week 28 PASI90 response, continuation group (n = 108); b) guselkumab, week 28 PASI90 non-response, continuation group (n = 63); c) guselkumab, week 28 PASI90 response, withdrawal group (n = 101)^a; d) adalimumab, week 28 PASI90 response, withdrawal group (n = 65)^a; e) adalimumab, week 28 PASI90 non-response, to guselkumab group (n = 67). ^a Patients initiated guselkumab 100 mg upon loss of 50% or greater of week 28 PASI response. DLQI: Dermatology Life Quality Index; NAPSI: Nail Psoriasis Severity Index; PASI: Psoriasis Area and Severity Index; q2w: every 2 weeks; q4w: every 4 weeks; q8w: every 8 weeks; Ra: randomization